Related Experiment Video

Updated: Aug 15, 2026

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells
06:32

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells

Published on: June 26, 2026

[Survival of children with cancer]

Jon Helgestad1, Bibbi Madsen

  • 1Barneklinikken, Haukeland Universitetssjukehus. jon.helgestad@aas.nja.dk

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|September 28, 2005
PubMed

Insights

Intensive pediatric cancer treatments improved survival rates for children diagnosed between 1992-2001. This approach significantly increased life years saved, demonstrating a cost-effective investment in pediatric oncology care.

Area of Science:

  • Pediatric Oncology
  • Clinical Research
  • Public Health

Background:

  • A decade of pediatric cancer patient data (1992-2001) from a Norwegian population of 1 million.
  • Focus on outcomes from intensive treatment regimens implemented during the study period.
  • Analysis of survival rates across different pediatric cancer types.

Purpose of the Study:

  • To present survival data for pediatric cancer patients (0-15 years) diagnosed between 1992 and 2001.
  • To evaluate the impact of intensive treatment on survival outcomes.
  • To assess the cost-effectiveness of pediatric cancer treatment in terms of saved life years.

Main Methods:

  • Retrospective analysis of survival data for 280 consecutive pediatric cancer patients.
  • Categorization of cancers into central nervous system tumors, leukemia, and solid tumors (including lymphomas).
  • Calculation of overall survival rates and saved life years, with cost-benefit analysis.

Main Results:

  • Overall survival rate of 78% (219/280) over 3-13 years post-diagnosis.
  • Subgroup survival rates: 75% for CNS tumors, 82% for leukemia, 79% for solid tumors.
  • Estimated 14,000 years of life saved, with an average cost of USD 2400 per saved year.

Conclusions:

  • Intensified pediatric cancer treatment regimens correlate with improved survival rates.
  • The economic benefits of pediatric cancer treatment, through future contributions of survivors, outweigh the initial costs.
  • This study highlights the value of investing in advanced pediatric cancer care.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...